Bronx, New York 10461


Purpose:

Resveratrol is a substance found in many plants, including grapes and red wine, which is widely used as a nutritional supplement. Studies in cells and lower animals show that resveratrol has many potential benefits, including prolonging lifespan, preventing cancer and heart disease and normalization of glucose metabolism. Although use of this agent shows great promise in the treatment and/or prevention of diabetes, there have been no studies reported to date in humans. As an initial step, this proposal is for a 6 week pilot study of resveratrol treatment in older adults with impaired glucose tolerance (IGT) in order to explore its effects on post-meal blood glucose metabolism. Preliminary studies will also be conducted to explore how resveratrol works by studying cellular function (in muscle samples obtained from study participants) and by testing resveratrol's effect on blood vessel function.


Criteria:

Inclusion Criteria: - impaired glucose tolerance Exclusion Criteria: - history of estrogen-dependent neoplasm - use of certain drugs: high dose statins, warfarin, antiepileptics - current treatment with anti-diabetes medications - impaired liver or kidney function


NCT ID:

NCT01375959


Primary Contact:

Principal Investigator
Jill Crandall, MD
Albert Einstein College of Medicine of Yeshiva University

Migdalia Reid, RN, MPH
Phone: 718-405-8271
Email: migdalia.reid@einstein.yu.edu


Backup Contact:

N/A


Location Contact:

Bronx, New York 10461
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.